[Results of treatment of porphyria cutanea tarda with bloodletting and chloroquine].
In 59 patients showing clear clinical and biochemical signs of porphyria cutanea tarda (PCT), we tested 3 different modes of therapy: 20 patients received combined treatment with repeated bleeding and chloroquine, 24 patients were exclusively treated with oral chloroquine in low doses, and 15 patients underwent repeated phlebotomy only. On an average, the time necessary for remission amounted to 3.5, 10.2, and 12.5 months, respectively. So the combined therapy proved the quickest. In patients with the acquired form of PCT, the pattern of urinary porphyrin normalized; those suffering from hereditary PCT retained the typically high uro/copro ratio. The values of the plasma porphyrin count and the plasma porphyrin index (PPI), which had been greatly enhanced before, went down to normal after therapy.
Seubert
S
S
Universitäts-Hautklinik Göttingen.
Seubert
A
A
Stella
A M
AM
Guzman
H
H
Batlle
A
A
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001815:Bloodletting; D002738:Chloroquine / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011164:Porphyrias / Q000628:therapy* / Q000652:urine; D011166:Porphyrins / Q000652:urine; D012871:Skin Diseases / Q000628:therapy* / Q000652:urine
D011166:Porphyrins; D002738:Chloroquine
Ergebnisse bei der Behandlung der Porphyria cutanea tarda mit Aderlass und Resochin.